https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2019.01639/full
Frontiers | Different Levels of Incomplete Terminal Pathway Inhibition by Eculizumab and the...
Background: Eculizumab blocks the lytic complement pathway by inhibiting C5 and has become the standard of care for certain complement-mediated diseases. Pre...
terminal pathway
https://pmc.ncbi.nlm.nih.gov/articles/PMC12789156/
Which Factors Influence Decisions to Withdraw from Eculizumab: A Qualitative Study of Patients...
Atypical haemolytic uremic syndrome (aHUS) is a rare life-threatening disease. Lifelong treatment with intravenous eculizumab every 2/3 weeks was recommended,...
https://www.hematology.org/education/clinicians/drug-resources/high-cost-hematologic-drug-access/eculizumab
Access Programs for Eculizumab - Hematology.org
Doctors wishing to treat patients with eculizumab must first register with the Risk Evaluation and Mitigation Strategy program (REMS).
access programseculizumabhematology
https://pmc.ncbi.nlm.nih.gov/articles/PMC12719173/
Efficacy of eculizumab discontinuation in atypical hemolytic uremic syndrome: a systematic review...
hemolytic uremic syndrome
https://medlineplus.gov/druginfo/meds/a612024.html
Eculizumab Injection: MedlinePlus Drug Information
Eculizumab Injection: learn about side effects, dosage, special precautions, and more on MedlinePlus
eculizumabinjectionmedlineplusdruginformation
https://www.frontiersin.org/journals/pediatrics/articles/10.3389/fped.2024.1404725/full
Frontiers | Application of eculizumab, a terminal complement inhibitor, in the management of...
Eculizumab, a recombined humanized monoclonal antibody which possesses high affinity for the complement protein C5, is a therapeutic agent utilized in the tr...
a terminalfrontiersapplicationeculizumab
https://www.cdc.gov/mmwr/volumes/66/wr/mm6627e1.htm?s_cid=mm6627e1_e
High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite...
Jul 7, 2017 - CDC report finds patients taking eculizumab at high risk for invasive meningococcal disease, even with vaccine.
high riskmeningococcal disease